At this point, it appears GTC gave away half the alpha-1 antitrypsin program to keep LFB onboard. (The existing agreement provides that GTC and LFB share development costs and future revenues.)
A cost-cutting measure perhaps? OK, give us the other shoe.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.